



Tumor Immune Microenvironment: A Holistic Approach Workshop

April 21-22, 2022 • San Diego and Virtually

#SITCworkshop




Society for Immunotherapy of Cancer

The role of metabolites in the tumor microenvironment

Marcia Haigis
Department of Cell Biology
Harvard Medical School


2022

Tiered view of tumor metabolism




Tumor cell metabolism


Tiered view of tumor metabolism




Tiered view of tumor metabolism





Tiered view of tumor metabolism




Nutrient use is altered in cancers



Cell proliferation is linked to metabolism



Ammonia promotes tumor proliferation




The TME is a unique niche


Altered levels of Fuels

Accumulation of inhibitory
metabolites: lactate, ammonia


Challenge: How do we target metabolism
specifically in the TME?



Metabolism in the T cell life cycle




T Cell activation initiates mitochondrial biogenesis



Ron Harel et al, Cell Met, 2016
Ron Harel et al, PNAS, 2018


Mitochondrial One Carbon Metabolism is induced with T cell activation




Steve Gygi

Not a typical biogenesis profile

A




B



Concepts


- T cells use similar fuels and signaling networks as many cancer cells.
- T cells become anabolic engines when activated.
- Not a typical biogenesis profile - suited for the anabolic demands of T cells.

What is the role of metabolism in the tumor microenvironment?




Janet Iwasa
Shraddha Nayak


Can we identify tumor versus T cell dependencies?



OT1 T cells




Ova+/- tumor cells





T cells + tumor cells
Co-culture

What is the metabolism of a cytotoxic T cell?




Cytotoxic T cells switch pyruvate utilization by increasing PC activity




Is PDH inhibition sufficient to increase anti-tumor cytotoxicity?


Co-culture



In vivo




Can we develop methods to rapidly separate co-cultures to study signaling and metabolism?








Elia et al, in revision

What is the metabolism of antigen-specific T cell-mediated killing of tumors?




Rowe et al, in preparation

Tumor cell contact *increases* CD8⁺ T cell serine biosynthesis




B16 Melanoma

One carbon metabolism




Serine is limiting in the TME



Conditioned Media vs RPMI





Tumor Interstitial fluid (In vivo)



Formate rescues diminished One Carbon metabolism in CD8+ T cells




Formate treatment synergizes with anti-PD-1




CD8+ T cells are required for benefits of formate


Tumor growth




Survival





Formate treatment impacts T cells and metabolism



Tiered view of tumor metabolism




Obesity is a cancer risk factor



“Body Fatness and Cancer – Viewpoint of the IARC Working Group”. NEJM (2016)

Using Mice to study tumor-immune mechanisms






System benefits

- antigen-specificity
- Tumors carry a reporter
- immune contributions
- Identify mechanisms
- Study causal mechanisms







Alison Ringel
MIT

T cells are required for increased tumor growth on high fat diet



*phenocopy with CD8⁺ T cell depletion
but not with CD4⁺ T cell depletion

High fat diet reduces the proportion of intratumoral CD8⁺ T cells




Day 12 Analysis of Tumor Immune Infiltrate

Challenges:



1. Many metabolic alterations are not reflected by transcription.
2. What are the metabolic states in an intact tissue?
3. What are the spatial relationships between immune cells and tumor cells?

CyCIF revealed a pattern of glycolytic proteins that differ with diet



Peter Sorger
Zoltan Maliga

Dimensional reduction and density-based clustering reveals core cell phenotypes




Peter Sorger
Greg Baker

Combining metabolite profiles with CyCIF cell reporters


Cyclic Immune Fluorescence (CyCIF)

CD8⁺ cell (green)

lactate colormap




MC38 tumors downregulate PHD3 expression with high fat diet



MC38-GFP RNA-seq (Day 12 Tumors, top metabolic genes)

PHD3 represses fat metabolism




Mitochondrial FAO **Repressed**

PHD3 loss increases fat oxidation




German N. J. Yoon H. et al., Mol Cell. 2016


Does diet-induced obesity cause a metabolic tug of war in tumors?




Surprise- obesity alters fatty acid profiles systemically vs. the tumor





Plasma
(Systemic Metabolism)




Tumor
(Local Metabolism)





PHD3 overexpression increases free fatty acids in the tumor microenvironment



PHD3 OE is sufficient to reduce tumor growth on HFD




**CD8⁺T cell-dependent




Does PHD3 stratify with obesity or immune activation markers in patients?


TCGA Data



Mouse Model




In colorectal cancer patients, PHD3-low samples are immunologically “cold”



How does obesity affect anti-tumor immunity?

- Obesity causes tumors to burn more fats.
- This depletes T cells of fats and impairs their function.
- Restore anti-tumor immunity with obesity by a metabolic gene manipulation in cancer.



Rathmell, NEJM, 2021

Ringel et al, Cell, 2020

Ongoing studies

- Identify additional mechanisms that improve anti-tumor immunity.
- Understand whether these mechanisms are important in other states, ages, metabolic conditions and diets.

Acknowledgements

Haigis Lab members

Olivia Dickert

Brandon Gassaway

Peter Georgiev

Iva Guberovic

James Han

Annie Hsieh

Sheila Johnson

Shakchhi Joshi

Liam Kelley

Kiran Kurmi

Stacy Mulei

Alison Ringel (2022 MIT)

Jaime Schneider

Sarah Tucker

Samantha Wong

Conghui Yao

Haejin Yoon

Arlene Sharpe (HMS)

Joshua Rabinowitz (Princeton)

Juan Carlos Canaverias

William Kaelin Jr. (DFCI)

Kevin Haigis (BIDMC)

Carla Kim (HMS, BCH)

Janet Iwasa (University of Utah)

Nathalie Agar (DFCI)

Peter Sorger (HMS-LSP)

Zoltan Maliga (LSP)

Greg Baker (LSP)



Former Lab members

Ilaria Elia (KU Leuven), Lydia Finley (MSKCC), Jefte Drijvers, Noga Ron (Technion Institute), Jessica Spinelli, Elma Zaganjor (Vanderbilt University), Giulia Notorangelo, Natalie German, Wen Yang

Funding Ludwig Cancer Center at Harvard, Paul Glenn Foundation for Medical Research, NIH/NIDDK, NIH/NCI, MSLC

Disclosures: Research funding from Agilent Technologies and Roche Pharmaceuticals
SAB of Guided Clarity